The GRIPAP1 Knockout HT29 Polyclonal Cells represent a genetically disrupted cell population generated via CRISPR/Cas9-mediated targeting of the GRIPAP1 gene in the human HT29 colorectal adenocarcinoma cell line. This product provides a heterogeneous polyclonal knockout pool, enabling the study of GRIPAP1 loss-of-function across a diverse cellular background. The use of CRISPR/Cas9 introduces targeted gene disruption, abolishing functional GRIPAP1 protein expression without reliance on single-cell clonal isolation. This polyclonal format is well-suited for pooled functional screens and phenotypic analyses in epithelial cell biology and colorectal cancer research.
The host cell line, HT29, is a widely utilized human colorectal adenocarcinoma model with epithelial morphology. Originally derived from a primary colon adenocarcinoma, HT29 cells retain the ability to express intestinal epithelial markers and undergo partial differentiation under specific culture conditions. They are an established platform for investigating colon cancer pathogenesis, epithelial barrier function, and differentiation programs. Their well-characterized signaling networks, including Wnt/??-catenin and MAPK pathways, provide a robust context for dissecting the role of endosomal trafficking regulators.
GRIPAP1 encodes a guanyl-nucleotide exchange factor (GEF) that specifically activates the small GTPases Rab4 and Rab21, serving as a critical node in endocytic recycling pathways. By catalyzing GDP-to-GTP exchange, GRIPAP1 promotes Rab4- and Rab21-mediated sorting from early endosomes, facilitating the rapid recycling of internalized transmembrane receptors back to the cell surface. Among its best-characterized substrates are AMPA-type glutamate receptors, whose synaptic abundance is tightly regulated by GRIPAP1-dependent recycling in neurons. The protein interacts with the scaffolding adapter GRIP1, which links it to receptor cargo, and operates within an intricate network involving upstream signals such as BDNF and glutamate, and downstream effectors that control receptor surface expression and endosomal dynamics.
In the colorectal cancer context of HT29 cells, GRIPAP1 knockout offers a unique opportunity to investigate how disruptions in endosomal recycling influence epithelial homeostasis and tumor cell behavior. GRIPAP1-dependent trafficking of receptors and junctional proteins may modulate cell polarity, migration, and invasive capacity??phenotypes central to colorectal cancer progression. The knockout model allows researchers to dissect the contribution of Rab4/Rab21 signaling to the maintenance of epithelial identity, while also exploring parallels with neurodevelopmental pathways implicated in autism spectrum disorder and intellectual disability.
Researchers can employ these polyclonal knockout cells in a broad range of experimental applications, including high-content screening for modulators of endocytic trafficking and validation of candidate drugs targeting Rab GTPase axes. Representative assays that leverage this model include western blotting to assess Rab4 and Rab21 activation, immunofluorescence staining for early endosome markers, and transferrin recycling kinetics to quantify endosomal flux. Co-immunoprecipitation of GRIP1 can probe the integrity of trafficking complexes, while RT-qPCR and flow cytometry enable monitoring of downstream gene expression and surface receptor turnover. Phospho-signaling arrays and migration/invasion assays further extend the utility of the model in cancer biology studies. For additional details, please contact Ascent Research.
